| pubmed-article:2782444 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C0232338 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C0040057 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:2782444 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:2782444 | pubmed:issue | 3 Pt 2 | lld:pubmed |
| pubmed-article:2782444 | pubmed:dateCreated | 1989-10-17 | lld:pubmed |
| pubmed-article:2782444 | pubmed:abstractText | We have shown in anesthetized open-chest dogs that recurrent platelet aggregation at the site of coronary artery stenosis and endothelial injury results in a pattern of cyclical variations in coronary blood flow (CFVs) and that serotonin and thromboxane A2 are important mediators of CFVs. In the present study, we tested the following hypotheses: 1) severe spontaneous reductions in coronary blood flow occur in awake closed-chest dogs with coronary artery stenoses and endothelial injury; 2) there is a progression from CFVs to persistent low coronary blood flow; and 3) serotonin and thromboxane A2 are important mediators of coronary blood flow reductions in this model. In 17 of 20 awake closed-chest unsedated dogs with experimental coronary artery stenoses and endothelial injury, either intermittent CFVs (n = 3), persistent low flow (n = 4), or progression from CFVs to low flow (n = 10) occurred during the first postoperative week. A serotonin receptor antagonist (ketanserin or LY 53857) or a thromboxane synthesis inhibitor (dazoxiben) or receptor antagonist (SQ 29548) abolished platelet-dependent CFVs in 80% of dogs. Thus 1) severe spontaneous reductions in coronary blood flow occur in awake closed-chest unsedated dogs with coronary artery stenoses and endothelial injury; 2) there is a progression from CFVs to persistent low coronary blood flow and final coronary artery occlusion; and 3) serotonin and thromboxane A2 are important mediators of coronary blood flow reductions in this experimental model. | lld:pubmed |
| pubmed-article:2782444 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2782444 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2782444 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2782444 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2782444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2782444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2782444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2782444 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2782444 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2782444 | pubmed:issn | 0002-9513 | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:WillersonJ... | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:AshtonJJ | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:BujaL MLM | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:GolinoPP | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:McNattJJ | lld:pubmed |
| pubmed-article:2782444 | pubmed:author | pubmed-author:EidtJ FJF | lld:pubmed |
| pubmed-article:2782444 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2782444 | pubmed:volume | 257 | lld:pubmed |
| pubmed-article:2782444 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2782444 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2782444 | pubmed:pagination | H873-82 | lld:pubmed |
| pubmed-article:2782444 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:meshHeading | pubmed-meshheading:2782444-... | lld:pubmed |
| pubmed-article:2782444 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2782444 | pubmed:articleTitle | Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs. | lld:pubmed |
| pubmed-article:2782444 | pubmed:affiliation | Department of Medicine (Cardiology Division), University of Texas Southwestern Medical Center, Dallas 75235. | lld:pubmed |
| pubmed-article:2782444 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2782444 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2782444 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2782444 | lld:pubmed |
